Inhibrx Biosciences, Inc. (INBX)
NASDAQ:INBX
Want to see INBX full AI Analyst Report?
Total Valuation
Inhibrx Biosciences Inc has a market cap or net worth of $1.88B. The enterprise value is $1.86B.
Market Cap$1.88B
Enterprise Value$1.86B
Share Statistics
Inhibrx Biosciences Inc has 14,607,286 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding14,607,286
Owned by Insiders9.70%
Owned by Institutions0.23%
Financial Efficiency
Inhibrx Biosciences Inc’s return on equity (ROE) is -17.52 and return on invested capital (ROIC) is -117.41%.
Return on Equity (ROE)-17.52
Return on Assets (ROA)-0.96
Return on Invested Capital (ROIC)-117.41%
Return on Capital Employed (ROCE)-1.20
Revenue Per Employee8.33K
Profits Per Employee-897.79K
Employee Count156
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Inhibrx Biosciences Inc is ―. Inhibrx Biosciences Inc’s PEG ratio is 0.08.
PE Ratio―
PS Ratio941.13
PB Ratio153.07
Price to Fair Value153.07
Price to FCF-9.42
Price to Operating Cash Flow-15.37
PEG Ratio0.08
Income Statement
In the last 12 months, Inhibrx Biosciences Inc had revenue of 1.30M and earned -140.06M in profits. Earnings per share was -9.04.
Revenue1.30M
Gross Profit-1.18M
Operating Income-135.03M
Pretax Income-140.05M
Net Income-140.06M
EBITDA-132.54M
Earnings Per Share (EPS)-9.04
Cash Flow
In the last 12 months, operating cash flow was -129.79M and capital expenditures -31.00K, giving a free cash flow of -129.82M billion.
Operating Cash Flow-129.79M
Free Cash Flow-129.82M
Free Cash Flow per Share-8.89
Dividends & Yields
Inhibrx Biosciences Inc pays an annual dividend of $0.85, resulting in a dividend yield of ―
Dividend Per Share$0.85
Dividend Yield―
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.19
52-Week Price Change944.53%
50-Day Moving Average73.47
200-Day Moving Average56.68
Relative Strength Index (RSI)70.23
Average Volume (3m)222.11K
Important Dates
Inhibrx Biosciences Inc upcoming earnings date is May 20, 2026, After Close (Confirmed).
Last Earnings DateMar 19, 2026
Next Earnings DateMay 20, 2026
Ex-Dividend Date―
Financial Position
Inhibrx Biosciences Inc as a current ratio of 3.93, with Debt / Equity ratio of 1338.82%
Current Ratio3.93
Quick Ratio3.93
Debt to Market Cap0.08
Net Debt to EBITDA0.13
Interest Coverage Ratio-11.07
Taxes
In the past 12 months, Inhibrx Biosciences Inc has paid 2.00K in taxes.
Income Tax2.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Inhibrx Biosciences Inc EV to EBITDA ratio is -9.10, with an EV/FCF ratio of -9.29.
EV to Sales927.90
EV to EBITDA-9.10
EV to Free Cash Flow-9.29
EV to Operating Cash Flow-9.29
Balance Sheet
Inhibrx Biosciences Inc has $124.22M in cash and marketable securities with $107.01M in debt, giving a net cash position of $17.21M billion.
Cash & Marketable Securities$124.22M
Total Debt$107.01M
Net Cash$17.21M
Net Cash Per Share$1.18
Tangible Book Value Per Share$0.52
Margins
Gross margin is -91.00%, with operating margin of -10386.54%, and net profit margin of -10773.46%.
Gross Margin-91.00%
Operating Margin-10386.54%
Pretax Margin-10773.31%
Net Profit Margin-10773.46%
EBITDA Margin-10195.54%
EBIT Margin-10386.54%
Analyst Forecast
The average price target for Inhibrx Biosciences Inc is $250.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$250.00
Price Target Upside193.01% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast550.00%
EPS Growth Forecast-107.76%